PUBLISHER: KuicK Research | PRODUCT CODE: 2000342
PUBLISHER: KuicK Research | PRODUCT CODE: 2000342
Global Bispecific Antibody Market Opportunity, Antibody Dosage, Patent, Price, Sales & Clinical Trials Outlook 2031
Global Bispecific Antibody Market Opportunity, Antibody Dosage, Patent, Price, Sales & Clinical Trials Outlook 2031 Report Findings & Highlights:
- Number Of Approved Bispecific Antibodies: 18
- Global, Regional Annual & Quarterly Sales Insight
- Global Bispecific Antibodies Market Opportunity: > USD 60 Billion By 2031
- Global Bispecific Antibodies Market In 2025: > USD 16 Billion
- Approved Antibodies Dosage, Patent, Pricing & Sales Insight
- Insight On Bispecific Antibodies Proprietary Platforms: >30 Platforms
- Comprehensive Insight On More than 550 Bispecific Antibodies In Clinical Trials
- Global Bispecific Antibodies Clinical Trials By Company, Indication & Phase
Need For Bispecific Antibodies & Why This Report?
Bispecific antibodies have been at the forefront of revolutionizing the horizon of immunotherapy and targeted therapy due to their potential to address the complexities of disease more effectively. With the persistence of challenges in cancer therapy, tumor heterogeneity, pathway redundancy, and treatment resistance limiting the full potential of single-agent therapy, there is a growing need for bispecific antibody therapeutics.
In the recent years, bispecific antibodies have witnessed substantial growth in the pharmaceutical market, especially in cancer therapy, where they have been shown to have substantial potential in harnessing the immune system to fight cancer. Apart from cancer, bispecific antibodies have also been evaluated for autoimmune diseases and beyond.
The global bispecific antibody market was estimated to be around US$ 16.9 Billion in 2025, with the US dominating the market, representing more than 60% of the total sales. With 18 bispecific antibodies already approved and regulatory filings for additional candidates in progress, the market is transitioning toward commercial maturity, supported by strong clinical progress and continued industry investment. This report, thus, serves as a valuable asset to pharmaceutical companies, investors and other stakeholders seeking realization in this continuously expanding market
Clinical Trials Insight Included In Report
Clinical trials have been at the core of bispecific antibody therapeutics development. With a large pipeline of bispecific antibodies under clinical investigation for various indications, particularly in oncology, bispecific antibodies are being evaluated for their potential to treat hematological malignancies and solid tumors such as non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).
The report undertakes a systematic and comprehensive analysis of clinical trials, covering first-in-human studies to confirmatory late-stage studies. Our analysis includes trial design, patient selection criteria, dose strategies, combination therapies, as well as special focus on studies conducted on relapsed or refractory patient populations, where bispecific antibodies have shown promising results. The emerging trends in clinical strategies are also exploring bispecific antibodies beyond oncology to other diseases such as autoimmune and inflammatory diseases, thereby expanding the potential application of bispecific antibodies. The progress of bispecific antibodies to late-stage development and regulatory submissions underscores the growing confidence in this class of drugs.
Major Companies Active In R&D Of Bispecific Antibodies
The bispecific antibody market has a competitive environment that is influenced by the active participation of both established pharmaceutical players as well as emerging biotechnology players. Established players such as JNJ, Amgen, Genmab and Roche are still at the forefront, backed by their financial capabilities, development expertise, as well as their existing oncology franchise. These players are continually expanding their bispecific antibody pipeline across various diseases, thereby not only strengthening their position but also expanding their presence in this class of drugs. However, they are also continuously diversifying their portfolios to remain competitive in the market.
On the other hand, emerging biotechnology players, such as Invenra, Biosion and Alligator Bioscience, are significantly contributing to the development of this market. These players are continuously entering this market with differentiated bispecific antibodies as well as novel potential applications, thereby adding to the competitive environment.
Technology Platforms, Collaborations & Agreements
Technological innovation is at the heart of bispecific antibody development. Various proprietary technologies have been developed to optimize bispecific antibody binding specificity, stability, manufacturability, and therapeutic efficacy. This includes formats such as BiTEs, dual variable domains, and other bispecific antibody formats.
Additionally, collaborations and licensing deals are an important factor in accelerating development pathways and expanding clinical utility. Such collaborations allow organizations to leverage mutual expertise and share developmental risks while improving global commercialization efforts. The Abbvie and RemeGen deal for RC148 is an excellent example of how strategic collaborations are driving innovation in next-generation bispecific antibodies, particularly in combination therapies.
Report Indicating Future Direction Of Bispecific Antibody Segment
The bispecific antibody market is expected to grow in the future with an optimistic outlook. The growth in this market is expected to be driven by clinical, technological, and therapeutic advances in the field. The increasing number of clinical trials in late stages suggests that more bispecific antibodies are expected to receive regulatory approval in the near future. This would further cement the position of bispecific antibodies in modern medicine.
Combination approach is expected to play an important role in driving bispecific antibodies in the future. This is particularly true in oncology indications where bispecific antibodies are expected to play an important part in combination therapies with other drugs. In addition to this, advances in bispecific antibodies are expected to drive better clinical outcomes in the near future.
In addition to oncology indications, bispecific antibodies are also being explored in autoimmune and inflammatory diseases. In conjunction with strong investment activity and strategic collaborations, bispecific antibodies are expected to play an important role in driving next-generation therapies in various disease indications.
Table of Contents
1. Reserch Methodology
2. Introduction To Bispecific Antibodies
3. Bispecific Antibody Combination Strategies
- 3.1 Chemotherapy
- 3.2 Targeted Therapy
- 3.3 Immunotherapy
- 3.4 Radiotherapy
4. Commercially Approved Bispecific Antibodies Insight
- 4.1 Company, Indication, Location & MOA
- 4.2 Bispecific Antibodies Granted Regulatory Designations
5. Bispecific Antibodies Proprietary Platforms
6. Global & Regional Bispecific Antibody Market Outlook
- 6.1 Yearly & Quarterly Sales Insight (2020 To 2025)
- 6.2 Approved Bispecific Antibodies Reimbursement & Coverage Policy
- 7.10 Global Bispecific Antibody Market Forecast 2031
7. Global Bispecific Antibody Market Trends By Region
- 7.1 US
- 7.2 Europe
- 7.3 China
- 7.4 UK
- 7.5 Japan
- 7.6 South Korea
- 7.7 Australia
- 7.8 Canada
- 7.9 Latin America
8. Approved Bispecific Antibodies - Clinical, Patent, Pricing & Sales Insight
- 8.1 Blincyto
- 8.2 Hemlibra
- 8.3 Rybrevant
- 8.4 Vabysmo
- 8.5 Lunsumio
- 8.6 Kaitani
- 8.7 Tecvayli
- 8.8 Columvi
- 8.9 Epkinly
- 8.10 Talvey
- 8.11 Elrexfio
- 8.12 Imdelltra
- 8.13 Ivonescimab
- 8.14 Ordspono
- 8.15 Ziihera
- 8.16 Bizengri
- 8.17 Korjuny
- 8.18 Lynozyfic
9. Global Bispecific Antibodies Clinical Trials By Company, Indication & Phase
- 9.1 Research
- 9.2 Preclinical
- 9.3 Phase I
- 9.4 Phase I/II
- 9.5 Phase II
- 9.6 Phase II
- 9.7 Phase-II/III
- 9.8 Phase III
- 9.9 Preregistration
- 9.10 Registered
10. Marketed Bispecific Antibodies Clinical Insight By Company, Country & Indication
11. Global Bispecific Antibodies Research & Market Trends By Indications
- 11.1 Cancer
- 11.1.1 Hematological Malignancies
- 11.1.2 Solid Cancers
- 11.2 Autoimmune & Inflammatory Diseases
- 11.3 Blood Disorders
- 11.4 Ocular Diseases
- 11.5 Microbial Diseases
12. Competitive Landscape
- 12.1 AbbVie
- 12.2 ABL Bio
- 12.3 Abzyme Therapeutics
- 12.4 Affimed Therapeutics
- 12.5 Akeso Biopharma
- 12.6 Alligator Bioscience
- 12.7 Alphamab Oncology
- 12.8 Amgen
- 12.9 Antibody Therapeutics
- 12.10 APITBIO
- 12.11 Aptevo Therapeutics
- 12.12 Astellas Pharma
- 12.13 AstraZeneca
- 12.14 BeOne Medicines
- 12.15 BioAtla
- 12.16 BioNTech
- 12.17 Biosion
- 12.18 BJ Bioscience
- 12.19 EpimAb Biotherapeutics
- 12.20 FutureGen Biopharmaceutical
- 12.21 Genentech
- 12.22 Genmab
- 12.23 Gensun Biopharma
- 12.24 Harbour BioMed
- 12.25 ImmuneOnco Biopharma
- 12.26 Innovent Biologics
- 12.27 Invenra
- 12.28 Jazz Pharmaceuticals
- 12.29 Johnson & Johnson
- 12.30 Kenjockety Biotechnology
- 12.31 LaNova Medicines Limited
- 12.32 Light Chain Bioscience
- 12.33 Lindis Biotech
- 12.34 Linton Pharm
- 12.35 Lyvgen Biopharma
- 12.36 MacroGenics
- 12.37 Merus
- 12.38 NovaBridge Biosciences
- 12.39 NovaRock Biotherapeutics
- 12.40 Novo Nordisk
- 12.41 Pfizer
- 12.42 Phanes Therapeutics
- 12.43 Prestige BioPharma
- 12.44 Regeneron Pharmaceuticals
- 12.45 Revitope
- 12.46 Roche
- 12.47 Summit Therapeutics
- 12.48 Virtuoso Therapeutics
- 12.49 Xencor
- 12.50 Zymeworks
List of Figures
- Figure 2-1: Bispecific Antibodies - Advantages
- Figure 3-1: Antibody-Chemotherapy Combination - Advantages
- Figure 3-2: Antibody-Chemotherapy Combination - Impending Challenges
- Figure 4-1: Blincyto - Mechanism Of Action
- Figure 4-2: Hemlibra - Mechanism Of Action
- Figure 4-3: Rybrevant - Mechanism Of Action
- Figure 4-4: Tecvayli - Mechanism Of Action
- Figure 4-5: Columvi - Mechanism Of Action
- Figure 4-6: Epkinly - Mechanism Of Action
- Figure 4-7: Talvey - Mechanism Of Action
- Figure 4-8: Elrexfio - Mechanism Of Action
- Figure 4-9: Imdelltra - Mechanism Of Action
- Figure 4-10: Ivonescimab - Mechanism Of Action
- Figure 4-11: Ziihera - Mechanism Of Action
- Figure 4-12: Lynozyfic - Mechanism Of Action
- Figure 4-13: Regulatory Designations - Benefits
- Figure 5-1: Multiclonics - Distinctive Characteristics
- Figure 5-2: Biclonics - Format
- Figure 5-3: ADAPTIR Bispecific Structure
- Figure 5-4: ADAPTIR-FLEX
- Figure 5-5: BEAT Platform - Multispecific Antibodies
- Figure 5-6: FIT-Ig - Proprietary Bispecific Platform
- Figure 5-7: BiClone format
- Figure 5-8: BioAtla CABs - Features
- Figure 5-9: BioAtla CABs - Benefits
- Figure 5-10: IMBiologic Bispecific Antibodies - Strategy
- Figure 5-11: IMBiologic Bispecific Antibodies - Mechanism Of Action
- Figure 5-12: Novel HBICE
- Figure 5-13: HBICE - Mechanism Of Action 1
- Figure 5-14: HBICE - Mechanism Of Action 2
- Figure 5-15: Phanes Therapeutics - PACbody Platform
- Figure 5-16: Phanes Therapeutics - SPECpair Platform
- Figure 5-17: Phanes Therapeutics - ATACCbody
- Figure 5-18: Numab Therapeutics - Technology
- Figure 5-19: Grabody I Platform - Mechanism Of Action
- Figure 5-20: Grabody I Platform - Mechanism Of Action
- Figure 5-21: 3-Step DuoBody Production Process
- Figure 5-22: DuoHexaBody Molecules - Schematic
- Figure 5-23: iTAb - Patented Structure
- Figure 5-24: iTAb - Mechanism of Action
- Figure 5-25: Synimmune - Proprietary Bispecific Antibody Format
- Figure 5-26: BiTE - Structure
- Figure 5-27: BiTE Molecule
- Figure 5-28: Sanyou Super Trillion Common Light Chain Antibody Discovery Platform
- Figure 5-29: ALiCE - Characteristics
- Figure 5-30: ALiCE - Schematic Diagram & Mechanism Of Action
- Figure 5-31: Abz2 Bispecific Platform
- Figure 5-32: Abz2 Bispecifics - Benefits
- Figure 5-33: Neo-X-Prime Bispecific Mechanism
- Figure 5-34: B-Body Bispecific Antibody - Structre
- Figure 5-35: xLinkBsAb - Structure
- Figure 5-36: PrecisionGATE Bispecific Antibody - Structure
- Figure 6-1: Global - Annual Bispecific Antibody Market (US$ Million), 2020-2025
- Figure 6-2: Global - Annual Bispecific Antibodies Market By Drugs (US$ Million), 2025
- Figure 6-3: Global - Bispecific Antibodies Market Shares By Drugs (%), 2025
- Figure 6-4: Global - Quarterly Bispecific Antibody Market (US$ Million), 2025
- Figure 6-5: Global - Annual Bispecific Antibody Market By Region (US$ Million), 2025
- Figure 6-6: Global - Bispecific Antibody Market Shares By Region (%), 2024
- Figure 6-7: US -Bispecific Antibody Market (US$ Million), 2020-2025
- Figure 6-8: US - Quarterly Bispecific Antibodies Market (US$ Million), 2025
- Figure 6-9: ROW -Bispecific Antibody Market Value (US$ Million), 2020-2025
- Figure 6-10: ROW - Quarterly Bispecific Antibodies Market (US$ Million), 2025
- Figure 6-11: Blincyto - Total Treatment Cost & Reimbursement Cost
- Figure 6-12: Blincyto - In Pocket & Out of Pocket Cost of Treatment
- Figure 6-13: Hemlibra - Total Treatment Cost & Reimbursement Cost
- Figure 6-14: Hemlibra - In Pocket & Out Of Pocket Cost Of Treatment
- Figure 6-15: Rybrevant - Maximum Coverage By Medicaid (US$)
- Figure 6-16: Rybrevant - Maximum Coverage By Private Insurance Coverage (US$)
- Figure 6-17: Vabysmo - Total Treatment Cost & Reimbursement Cost
- Figure 6-18: Vabysmo - In Pocket & Out Of Pocket Cost Of Treatment
- Figure 6-19: Global - Bispecific Antibody Market Opportunity Assessment (US$ Billion), 2026 - 2031
- Figure 7-1: US - Bispecific Antibodies Approval
- Figure 8-1: Blincyto - Approval Year By Region
- Figure 8-2: Blincyto - Patent Filing & Expiration Year
- Figure 8-3: Blincyto - Treatment Regimen Cycles (Weeks)
- Figure 8-4: Blincyto - Duration Of Treatment Phase & Resting Phase In Induction & Consolidation Cycles For Treatment Of MRD-Positive B-Cell Precursor (Days)
- Figure 8-5: Blincyto - Recommended Number Of Induction & Consolidation Treatment Cycle For Relapsed B-Cell Precursor ALL
- Figure 8-6: Blincyto - Duration Of Single Induction, Consolidation, Continued Cycle & Full Treatment For Relapsed B-Cell Precursor ALL (Weeks)
- Figure 8-7: Global - Blincyto Sales (US$ Million), 2020-2025
- Figure 8-8: Global - Blincyto Quaterly Sales (US$ Million), 2025
- Figure 8-9: US - Blincyto Sales (US$ Million), 2020-2025
- Figure 8-10: US - Blincyto Quaterly Sales (US$ Million), 2025
- Figure 8-11: ROW - Blincyto Sales (US$ Million), 2020-2025
- Figure 8-12: ROW - Blincyto Quaterly Sales (US$ Million), 2025
- Figure 8-13: Hemlibra - Approval Years By Region
- Figure 8-14: Hemlibra - Cost Per Unit & Supply Of 30 mg/mL Subcutaneous Injection By Volume (US$), March'2026
- Figure 8-15: Hemlibra - Cost per Unit & Supply of 150 mg/mL Subcutaneous Injection Of Different Volumes (US$), March'2026
- Figure 8-16: Hemlibra - Recommended Loading & Maintenance Dose For Treatment Of Hemophilia (mg/kg/Week)
- Figure 8-17: Global - Hemlibra Sales (US$ Million), 2020-2025
- Figure 8-18: Global - Hemlibra Quaterly Sales (US$ Million), 2025
- Figure 8-19: Global - US v/s ROW Sales (US$ Million), 2025
- Figure 8-20: Global - Hemlibra Sales By Region (US$ Million), 2025
- Figure 8-21: Global - Hemlibra Sales By Region (%), 2025
- Figure 8-22: US - Hemlibra Sales (US$ Million), 2020-2025
- Figure 8-23: US - Hemlibra Quaterly Sales (US$ Million), 2025
- Figure 8-24: Europe - Hemlibra Sales (US$ Million), 2020-2025
- Figure 8-25: Europe - Hemlibra Quaterly Sales (US$ Million), 2025
- Figure 8-26: Japan - Hemlibra Sales (US$ Million), 2020-2025
- Figure 8-27: Japan - Hemlibra Quaterly Sales (US$ Million), 2025
- Figure 8-28: ROW - Hemlibra Sales (US$ Million), 2020-2025
- Figure 8-29: ROW - Hemlibra Quaterly Sales (US$ Million), 2025
- Figure 8-30: Rybrevant - Patent Filing & Expiration Year
- Figure 8-31: Rybrevant - Price Per Unit & Supply Of Intravenous Solution (US$), March'2026
- Figure 8-32: Rybrevant - Recommended Dose Per Cycle By Body Weight (mg)
- Figure 8-33: Rybrevant - Dose Reduction In Patients With Weight Less Than 80 kg (mg)
- Figure 8-34: Rybrevant - Dose Reduction in Patients with Weight more than 80 Kg (mg)
- Figure 8-35: Global - Rybrevant Sales (US$ Million), 2024-2025
- Figure 8-36: Global - Rybrevant Quaterly Sales (US$ Million), 2025
- Figure 8-37: US - Rybrevant Sales ((US$ Million), 2024-2025
- Figure 8-38: US - Rybrevant Quaterly Sales (US$ Million), 2025
- Figure 8-39: ROW - Rybrevant Sales (US$ Million), 2024-2025
- Figure 8-40: ROW - Rybrevant Quaterly Sales (US$ Million), 2025
- Figure 8-41: Vabysmo - Approval Year By Region
- Figure 8-42: Rybrevant - Patent Filing & Expiration Year
- Figure 8-43: Vabysmo - Price Per Unit & Supply Of Intravitreal Solution (US$), March'2026
- Figure 8-44: Global - Vabysmo Sales (US$ Million), 2022-2025
- Figure 8-45: Global - Vabysmo Quaterly Sales (US$ Million), 2025
- Figure 8-46: Global - US v/s ROW Sales (US$ Million), 2025
- Figure 8-47: Global - Vabysmo Sales By Region (US$ Million), 2025
- Figure 8-48: Global - Vabysmo Sales By Region (%), 2025
- Figure 8-49: US - Vabysmo Sales (US$ Million), 2022-2025
- Figure 8-50: US - Vabysmo Quaterly Sales (US$ Million), 2025
- Figure 8-51: Europe - Vabysmo Sales (US$ Million), 2022-2025
- Figure 8-52: Europe - Vabysmo Quaterly Sales (US$ Million), 2025
- Figure 8-53: Japan - Vabysmo Sales (US$ Million), 2022-2025
- Figure 8-54: Japan - Vabysmo Quaterly Sales (US$ Million), 2025
- Figure 8-55: ROW - Vabysmo Sales (US$ Million), 2022-2025
- Figure 8-56: ROW - Vabysmo Quaterly Sales (US$ Million), 2025
- Figure 8-57: Lunsumio - Approval Years By Region
- Figure 8-58: US - Price Per Unit & Supply of Lunsumio Intravenous Solution (US$), March'2026
- Figure 8-59: EU - Price Per Unit & Supply of Lunsumio Intravenous Solution (US$), March'2026
- Figure 8-60: Global - Lunsumio Sales (US$ Million), 2022-2025
- Figure 8-61: Global - Lunsumio Quaterly Sales (US$ Million), 2025
- Figure 8-62: Global - US v/s ROW Sales (US$ Million), 2025
- Figure 8-63: Global - Lunsumio Sales By Region (US$ Million), 2025
- Figure 8-64: Global - Lunsumio Sales By Region (%), 2025
- Figure 8-65: US - Lunsumio Sales (US$ Million), 2022-2025
- Figure 8-66: US - Lunsumio Quaterly Sales (US$ Million), 2025
- Figure 8-67: Europe - Lunsumio Sales (US$ Million), 2022-2025
- Figure 8-68: Europe - Lunsumio Quaterly Sales (US$ Million), 2025
- Figure 8-69: Japan - Lunsumio Sales (US$ Million), 2022-2025
- Figure 8-70: Japan - Lunsumio Quaterly Sales (US$ Million), 2025
- Figure 8-71: ROW - Lunsumio Sales (US$ Million), 2022-2025
- Figure 8-72: ROW - Lunsumio Quaterly Sales (US$ Million), 2025
- Figure 8-73: China - Kaitani Sales (US$ Million), 2022-2023
- Figure 8-74: Tecvayli - Approval Years by Region
- Figure 8-75: Tecvayli - Patent Acceptance & Expiration Year
- Figure 8-76: US - Cost Per Unit & Supply Of Tecvayli Subcutaneous Solution (US$), March'2026
- Figure 8-77: EU - Cost of Supply Of Tecvayli Subcutaneous Solution (US$), March'2026
- Figure 8-78: Global - Tecvayli Sales (US$ Million), 2022-2025
- Figure 8-79: Tecvayli - US v/s ROW Sales (US$ Million), 2025
- Figure 8-80: Tecvayli - US v/s ROW Sales (%), 2025
- Figure 8-81: Global - Tecvayli Quaterly Sales (US$ Million), 2025
- Figure 8-82: US - Tecvayli Sales (US$ Million), 2022-2025
- Figure 8-83: US - Tecvayli Quaterly Sales (US$ Million), 2025
- Figure 8-84: ROW - Tecvayli Sales (US$ Million), 2022-2025
- Figure 8-85: ROW - Tecvayli Quaterly Sales (US$ Million), 2025
- Figure 8-86: Columvi - Approval Year By Region
- Figure 8-87: US - Price Per Unit & Supply Of Columvi Intravenous Solution (US$), March'2026
- Figure 8-88: EU - Price Of Supply Of Columvi Intravenous Solution (US$), March'2026
- Figure 8-89: Global - Columvi Sales (US$ Million), 2023-2025
- Figure 8-90: Global - Columvi Quaterly Sales (US$ Million), 2025
- Figure 8-91: Global - US v/s ROW Sales (US$ Million), 2025
- Figure 8-92: Global - Columvi Sales By Region (US$ Million), 2025
- Figure 8-93: Global - Columvi Sales By Region (%), 2025
- Figure 8-94: US - Columvi Sales (US$ Million), 2023-2025
- Figure 8-95: US - Columvi Quaterly Sales (US$ Million), 2025
- Figure 8-96: Europe - Columvi Sales (US$ Million), 2023-2025
- Figure 8-97: Europe - Columvi Quaterly Sales (US$ Million), 2025
- Figure 8-98: ROW - Columvi Sales (US$ Million), 2023-2025
- Figure 8-99: ROW - Columvi Quaterly Sales (US$ Million), 2025
- Figure 8-100: Epkinly - Approval Year By Region
- Figure 8-101: US - Cost Per Unit & Supply Of Epkinly Subcutaneous Solution (US$), March'2026
- Figure 8-102: EU - Cost Of Supply Of Epkinly Subcutaneous Solution (US$), March'2026
- Figure 8-103: Global - Epkinly Sales (US$ Million), 2023-2025
- Figure 8-104: Global - Epkinly Sales Reported By Genmab (US$ Million), 2023-2025
- Figure 8-105: Global - Epkinly Sales Reported By AbbVie (US$ Million), 2023-2025
- Figure 8-106: Global - Epkinly Quaterly Sales (US$ Million), 2025
- Figure 8-107: Talvey - Approval Year By Region
- Figure 8-108: Talquetamab - FDA & EMA Designation Year
- Figure 8-109: Talvey - Patent Acceptance & Expiration Year
- Figure 8-110: US - Price Per Unit & Supply Of Talvey Intravenous Solution (US$), March'2026
- Figure 8-111: EU - Price Per Supply Of Talvey Intravenous Solution (US$), March'2026
- Figure 8-112: Global - Talvey Sales (US$ Million), 2024-2025
- Figure 8-113: Global - Talvey Quaterly Sales (US$ Million), 2025
- Figure 8-114: US - Talvey Sales ((US$ Million), 2024-2025
- Figure 8-115: US - Talvey Quaterly Sales (US$ Million), 2025
- Figure 8-116: ROW - Talvey Sales (US$ Million), 2024-2025
- Figure 8-117: ROW - Talvey Quaterly Sales (US$ Million), 2025
- Figure 8-118: Elrexfio - Approval Year by Region
- Figure 8-119: Elranatamab - FDA & EMA Designation Year
- Figure 8-120: US - Price Per Unit & Supply Of Elrexfio Subcutaneous Solution (US$), March'2026
- Figure 8-121: Global - Elrexfio Sales (US$ Million), 2023-2025
- Figure 8-122: Global - Elrexfio Quaterly Sales (US$ Million), 2025
- Figure 8-123: US - Elrexfio Sales (US$ Million), 2023-2025
- Figure 8-124: Global - Elrexfio Quaterly Sales (US$ Million), 2025
- Figure 8-125: ROW - Elrexfio Sales (US$ Million), 2023-2025
- Figure 8-126: Global - Elrexfio Quaterly Sales (US$ Million), 2025
- Figure 8-127: Imdelltra - Approval Year By Region
- Figure 8-128: US - Price Of Supply Of Imdelltra Intravenous Powder (US$), March'2026
- Figure 8-129: EU - Price Of Supply Of Imdelltra Intravenous Powder (US$), March'2026
- Figure 8-130: Global - Imdelltra Sales (US$ Million), 2024-2025
- Figure 8-131: Global - Imdelltra Quaterly Sales (US$ Million), 2025
- Figure 8-132: US - Imdelltra Sales ((US$ Million), 2024-2025
- Figure 8-133: US - Imdelltra Quaterly Sales (US$ Million), 2025
- Figure 8-134: ROW - Imdelltra Sales (US$ Million), 2024-2025
- Figure 8-135: ROW - Imdelltra Quaterly Sales (US$ Million), 2025
- Figure 8-136: EU - Price Of Supply Of Ordspono Intravenous Powder (US$), March'2026
- Figure 8-137: US & EU - Price Per Unit & Supply Of Ziihera (US$), March'2026
- Figure 8-138: Global - Ziihera Sales (US$ Million), 2024-2025
- Figure 8-139: Global - Ziihera Quaterly Sales (US$ Million), 2025
- Figure 8-140: Zenocutuzumab - Active Patents
- Figure 8-141: US - Price Of Supply Of Bizengri Intravenous Solution (US$), March'2026
- Figure 8-142: US - Price Per Unit & Supply of Lynozyfic Intravenous Solution, March'2026
- Figure 9-1: Global - Number of Bispecific Antibodies In Clinical Pipeline By Phase, 2026 Till 2031
- Figure 11-1: MK-1045-002 Phase I/II Study (NCT05579132) - Initiation & Completion Year
- Figure 11-2: LINKER-MM1 Phase I/II Study (NCT03761108) - Initiation & Completion Year
- Figure 11-3: LBL-034-CN001 Phase I/II Study (NCT06049290) - Initiation & Completion Year
- Figure 11-4: LINKER-SMM1 Phase II Study (NCT05955508) - Initiation & Completion Year
- Figure 11-5: EPCORE FL-1 Phase III Study (NCT05409066) - Initiation & Completion Year
- Figure 11-6: EPCORE(TM) NHL-2 Phase I/II Study (NCT04663347) - Initiation & Completion Year
- Figure 11-7: COALITION Phase I/II Study (NCT04914741) - Initiation & Completion Year
- Figure 11-8: ELM-2 Phase II Study (NCT03888105) - Initiation & Completion Year
- Figure 11-9: OLYMPIA-1 Phase III Study (NCT06091254) - Initiation & Completion Year
- Figure 11-10: OLYMPIA-2 Phase III Study (NCT06097364) - Initiation & Completion Year
- Figure 11-11: OLYMPIA-3 Phase III Study (NCT06091865) - Initiation & Completion Year
- Figure 11-12: OLYMPIA-4 Phase III Study (NCT06230224) - Initiation & Completion Year
- Figure 11-13: OLYMPIA-5 Phase III Study (NCT06149286) - Initiation & Completion Year
- Figure 11-14: HX009-I-01 Phase I Study (NCT05731752) - Initiation & Completion Year
- Figure 11-15: HX009-II-01 Phase I/II Study (NCT04886271) - Initiation & Completion Year
- Figure 11-16: DeLLphi-304 Phase III Study (NCT05740566) - Initiation & Completion Year
- Figure 11-17: HARMONi Phase III Study (NCT06396065) - Initiation & Completion Year
- Figure 11-18: HARMONi-6 Phase III Study (NCT05840016) - Initiation & Completion Year
- Figure 11-19: HERIZON-GEA-01 Phase III Study (NCT05152147) - Initiation & Completion Year
- Figure 11-20: eNRGy Phase II Study (NCT02912949) - Initiation & Completion Year
- Figure 11-21: AK104-303 Phase III Study (NCT02912949) - Initiation & Completion Year
- Figure 11-22: AK104-308 Phase II Study (NCT06371157) - Initiation & Completion Year
- Figure 11-23: TWINPEAK Phase I/II Study (NCT05482893) - Initiation & Completion Year
- Figure 11-24: SKYBRIDGE Phase I/II Study (NCT05652686) - Initiation & Completion Year
- Figure 11-25: CIBI389A101 Phase I Study (NCT02912949) - Initiation & Completion Year
- Figure 11-26: INCA 33890-101 Phase I Study (NCT05836324) - Initiation & Completion Year
- Figure 11-27: INCA033890-303 Phase III Study (NCT07284849) - Initiation & Completion Year
- Figure 11-28: COMPANION-002 Phase II/III Study (NCT05506943) - Initiation & Completion Year
- Figure 11-29: BNT327-02 Phase II Study (NCT06449222) - Initiation & Completion Year
- Figure 11-30: RNDO-564-001 Phase I Study (NCT07218003) - Initiation & Completion Year
- Figure 11-31: LBL-033-CN001 Phase I/II Study (NCT05779163) - Initiation & Completion Year
- Figure 11-32: NAV-240-201 Phase II Study (NCT07384975) - Initiation & Completion Year
- Figure 11-33: ZL-1503-001 Phase I Study (NCT07235384) - Initiation & Completion Year
- Figure 11-34: FRONTIER 4 Phase III Study (NCT05685238) - Initiation & Completion Year
- Figure 11-35: NXTAGE Phase I/II Study (NCT05987449) - Initiation & Completion Year
- Figure 11-36: HMB-001-CL101 Phase II Study (NCT06211634) - Initiation & Completion Year
- Figure 11-37: PEAK Phase III Study (NCT06990399) - Initiation & Completion Year
- Figure 11-38: PINNACLE Phase III Study (NCT06996080) - Initiation & Completion Year
- Figure 11-39: RV584 Phase I Study (NCT05890963) - Initiation & Completion Year
- Figure 11-40: 001965-I Phase I Study (NCT06585891) - Initiation & Completion Year
List of Tables
- Table 3-1: Clinically Approved Bispecific Antibody Combinations
- Table 3-2: Bispecific Antibody & Chemotherapy Combinations In Clinical Trials
- Table 3-3: Bispecific Antibody & Targeted Therapy Combinations In Clinical Trials
- Table 3-4: Bispecific Antibody & Immunotherapy Combinations In Clinical Trials
- Table 3-5: Bispecific Antibody & Radiotherapy Combinations In Clinical Trials
- Table 4-1: Approved Bispecific Antibodies
- Table 4-2: US - Bispecific Antibodies With Regulatory Designations
- Table 4-3: EU - Bispecific Antibodies With Regulatory Designations
- Table 4-4: China - Bispecific Antibodies with Regulatory Designations
- Table 6-1: Epkinly - Billing Unit Application For Doses
- Table 6-2: Talvey - Coverage Summary
- Table 6-3: Talvey - Coding Summary
- Table 6-4: Elrexfio - HCPCS Codes
- Table 6-5: Elrexfio - HCPCS Modifiers
- Table 6-6: Imdelltra - Payer Coverage & Reimbursement Details
- Table 6-7: Ziihera - ICD-10-CM Codes
- Table 6-8: Ziihera - ICD-10-PCS Codes
- Table 6-9: LYNOZYFIC - HCPCS code
- Table 8-1: Blincyto - Active Patents
- Table 8-2: Blincyto - Recommended Dosage & Schedule For The Treatment of MRD-Positive B-Cell Precursor ALL
- Table 8-3: Blincyto - Recommended Dosage & Schedule for Treatment Of Relapsed Or Refractory B-Cell Precursor ALL
- Table 8-4: Blincyto - Recommended Dosage & Schedule For Treatment Of Relapsed Or Refractory B-Cell Precursor ALL
- Table 8-5: Rybrevant - Premedication
- Table 8-6: Rybrevant - Dose Reductions For Adverse Reactions
- Table 8-7: Rybrevant - Recommended Dosage Modifications For Adverse Reactions
- Table 8-8: Lunsumio - Recommended Treatment Cycles
- Table 8-9: Lunsumio - Recommended Premedications
- Table 8-10: Lunsumio - Recommendations For Management Of Cytokine Release Syndrome
- Table 8-11: Tecvayli - Dosing Schedule
- Table 8-12: Tecvayli - Recommended Dosage Modifications For Adverse Reactions
- Table 8-13: Columvi - Dosing Schedule (21-Day Treatment Cycles)
- Table 8-14: Columvi - Premedications To Be Administered
- Table 8-15: Columvi - Recommendations For Management Of Cytokine Release Syndrome
- Table 8-16: Columvi - Recommended Dosage Modification For Neurologic Toxicity (Including ICANS)
- Table 8-17: Columvi - Recommended Dosage Modifications For Other Adverse Reactions
- Table 8-18: Epkinly - Dosage Schedule
- Table 8-19: Epkinly - Recommendations For Management Of Cytokine Release Syndrome
- Table 8-20: Epkinly - Recommendations for Management of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
- Table 8-21: Epkinly - Recommended Dosage Modifications For Other Adverse Reactions
- Table 8-22: Talvey - Weekly Dosing Schedule
- Table 8-23: Talvey - Biweekly Dosing Schedule
- Table 8-24: Talvey - Recommendations For Management of CRS
- Table 8-25: Talvey - Recommendations For Management Of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
- Table 8-26: Talvey - Recommendations For Management Of Neurologic Toxicity (excluding ICANS)
- Table 8-27: Talvey - Recommended Dosage Modifications For Other Adverse Reactions
- Table 8-28: Elrexfio - Dosing Schedule
- Table 8-29: Elrexfio - Recommendations For Management Of CRS
- Table 8-30: Elrexfio - Recommended Dosage Modifications For Other Adverse Reactions
- Table 8-31: Ordspono - Recommended Dose
- Table 8-32: Ordspono - Premedications & Post-Medications For Patients With r/r FL Or r/r DLBCL
- Table 8-33: Ordspono - Recommendations For Management Of Cytokine Release Syndrome
- Table 8-34: Ziihera - Dosage Modifications For Adverse Reactions
- Table 8-35: Bizengri - Premedications Prior To Infusions
- Table 8-36: Bizengri - Premedications Prior to Infusions
- Table 8-37: Bizengri - Recommended Dosage Modifications & Management For Adverse Reactions
- Table 8-38: Korjuny - Dosing Schedule
- Table 8-39: Lynozyfic - Dosing Schedule
- Table 8-40: Lynozyfic - Recommendations for Restarting Therapy After a Dose Delay
